Some sterile injectables could see higher reimbursement . . .

Gottlieb: FDA, CMS Eye Reimbursement Changes To Stem Drug Shortages

By Beth Wang / July 19, 2018 at 8:25 PM
FDA, through its Drug Shortages Task Force, will work with CMS to revamp reimbursement policies for critical access drugs, especially sterile injectables, to incentivize manufacturers to invest in and modernize their manufacturing processes and spur development of critical access drugs, FDA Commissioner Scott Gottlieb said during a policy summit on Tuesday (July 17). The two agencies, along with the Department of Veterans Affairs (VA) are considering changing the wholesale acquisition cost or average sales price for a subset of drugs...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.